Sinead Gaubert

Sinead Gaubert

Auto-generated profile, based on publicly available information

Sinead Gaubert

Université Paris Cité, Inserm UMRS 1144 Therapeutic Optimization in Neuropsychopharmacology, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2019 in Brain
Verified
Journal Article
Closed access
SGSinead Gaubert
Sinead Gaubert
FRFederico Raimondo
Federico Raimondo
MHMarion Houot
Marion Houot
MCMarie-Constance Corsi
Marie-Constance Corsi
LNLionel Naccache
Lionel Naccache
AIAlzheimer’s Disease Neuroimaging Initiative
Alzheimer’s Disease Neuroimaging Initiative
Early biomarkers are needed to identify individuals at high risk of preclinical Alzheimer’s disease and to better understand the pathophysiological processes of disease progression. Preclinical Alzheimer’s disease EEG changes would be non-invasive and cheap screening tools and could also help to predict future progression to clinical Alzheimer’s disease. However, the impact of amyloid-β deposition and neurodegeneration on EEG biomarkers needs to be elucidated. We included participants from the INSIGHT-preAD cohort, which is an ongoing single-centre multimodal observational study that was designed to identify risk factors and markers of progression to clinical Alzheimer’s disease in 318 cognitively normal individuals aged 70–85 years with a subjective memory complaint. We divided the subjects into four groups, according to their amyloid status (based on 18F-florbetapir PET) and neurodegeneration status (evidenced by 18F-fluorodeoxyglucose PET brain metabolism in Alzheimer’s disease signature regions). The first group was amyloid-positive and neurodegeneration-positive, which corresponds to stage 2 of preclinical Alzheimer’s disease. The second group was amyloid-positive and neurodegeneration-negative, which corresponds to stage 1 of preclinical Alzheimer’s disease. The third group was amyloid-negative and neurodegeneration-positive, which corresponds to ‘suspected non-Alzheimer’s pathophysiology’. The last group was the control group, defined by amyloid-negative and neurodegeneration-negative subjects. We analysed 314 baseline 256-channel high-density eyes closed 1-min resting state EEG recordings. EEG biomarkers included spectral measures, algorithmic complexity and functional connectivity assessed with a novel information-theoretic measure, weighted symbolic mutual information. The most prominent effects of neurodegeneration on EEG metrics were localized in frontocentral regions with an increase in high frequency oscillations (higher beta and gamma power) and a decrease in low frequency oscillations (lower delta power), higher spectral entropy, higher complexity and increased functional connectivity measured by weighted symbolic mutual information in theta band. Neurodegeneration was associated with a widespread increase of median spectral frequency. We found a non-linear relationship between amyloid burden and EEG metrics in neurodegeneration-positive subjects, either following a U-shape curve for delta power or an inverted U-shape curve for the other metrics, meaning that EEG patterns are modulated differently depending on the degree of amyloid burden. This finding suggests initial compensatory mechanisms that are overwhelmed for the highest amyloid load. Together, these results indicate that EEG metrics are useful biomarkers for the preclinical stage of Alzheimer’s disease.

1 September 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
SGSinead Gaubert
Sinead Gaubert
MHMarion Houot
Marion Houot
FRFederico Raimondo
Federico Raimondo
MAManon Ansart
Manon Ansart
MCMarie-Constance Corsi
Marie-Constance Corsi
Stephane EpelbaumStephane Epelbaum
Stephane Epelbaum

29 March 2025 in EBioMedicine
Verified
Journal Article
Open access
SGSinead Gaubert
Sinead Gaubert
PGPilar Garces
Pilar Garces
JHJörg Hipp
Jörg Hipp
RBRicardo Bruña
Ricardo Bruña
MLMaria Eugenia Lopéz
Maria Eugenia Lopéz
DEDenis-Alexander Engemann
Denis-Alexander Engemann
Developing non-invasive and affordable biomarkers to detect Alzheimer's disease (AD) at a prodromal stage is essential, particularly in the context of new disease-modifying therapies. Mild cognitive impairment (MCI) is a critical stage preceding dementia, but not all patients with MCI will progress to AD. This study explores the potential of magnetoencephalography (MEG) to predict cognitive decline from MCI to AD dementia. We analysed resting-state MEG data from the BioFIND dataset including 117 patients with MCI among whom 64 developed AD dementia (AD progression), while 53 remained cognitively stable (stable MCI), using spectral analysis. Logistic regression models estimated the additive explanation of selected clinical, MEG, and MRI variables for AD progression risk. We then built a high-dimensional classification model to combine all modalities and variables of interest. MEG 16-38Hz spectral power, particularly over parieto-occipital magnetometers, was significantly reduced in the AD progression group. In logistic regression models, decreased MEG 16-38Hz spectral power and reduced hippocampal volume/total grey matter ratio on MRI were independently linked to higher AD progression risk. The data-driven classification model confirmed, among other factors, the complementary information of MEG covariance (AUC = 0.74, SD = 0.13) and MRI cortical volumes (AUC = 0.77, SD = 0.14) to predict AD progression. Combining all inputs led to markedly improved classification scores (AUC = 0.81, SD = 0.12). These findings highlight the potential of spectral power and covariance as robust non-invasive electrophysiological biomarkers to predict AD progression, complementing other diagnostic measures, including cognitive scores and MRI. This work was supported by: Fondation pour la Recherche Médicale (grant FDM202106013579).

Verified
Journal Article
Open access
PDF file
MLMatthieu Lilamand
Matthieu Lilamand
JCJosué Clery
Josué Clery
AVAgathe Vrillon
Agathe Vrillon
FMFrançois Mouton-Liger
François Mouton-Liger
ECEmmanuel COGNAT
Emmanuel COGNAT
CPClaire Paquet
Claire Paquet
Background: Alpha-synuclein, abnormally aggregated in Dementia with Lewy Bodies (DLB), could represent a potential biomarker to improve the differentiation between DLB and Alzheimer’s disease (AD). Our main objective was to compare Cerebrospinal Fluid (CSF) alpha-synuclein levels between patients with DLB, AD and Neurological Control (NC) individuals. Methods: In a monocentric retrospective study, we assessed CSF alpha-synuclein concentration with a validated ELISA kit (ADx EUROIMMUN) in patients with DLB, AD and NC from a tertiary memory clinic. Between-group comparisons were performed, and Receiver Operating Characteristic analysis was used to identify the best CSF alpha-synuclein threshold. We examined the associations between CSF alpha-synuclein, other core AD CSF biomarkers and brain MRI characteristics. Results: We included 127 participants (mean age: 69.3 ± 8.1, Men: 41.7%). CSF alpha-synuclein levels were significantly lower in DLB than in AD (1.28 ± 0.52 ng/mL vs. 2.26 ± 0.91 ng/mL, respectively, p < 0.001) without differences due to the stage of cognitive impairment. The best alpha-synuclein threshold was characterized by an Area Under the Curve = 0.85, Sensitivity = 82.0% and Specificity = 76.0%. CSF alpha-synuclein was associated with CSF AT(N) biomarkers positivity (p < 0.01) but not with hippocampal atrophy or white matter lesions. Conclusion: CSF Alpha-synuclein evaluation could help to early differentiate patients with DLB and AD in association with existing biomarkers.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
SGSinead Gaubert
Sinead Gaubert
FRFederico Raimondo
Federico Raimondo
MHMarion Houot
Marion Houot
MCMarie‐Constance Corsi
Marie‐Constance Corsi
LNLionel Naccache
Lionel Naccache
TGthe Alzheimer’s Disease Neuroimaging Initiative, the MEMENTO study group and the INSIGHT‐preAD study group
the Alzheimer’s Disease Neuroimaging Initiative, the MEMENTO study group and the INSIGHT‐preAD study group

26 March 2019 in Revue Neurologique
Verified
Journal Article
Closed access
SGSinead Gaubert
Sinead Gaubert
FRFederico Raimondo
Federico Raimondo
MHMarion Houot
Marion Houot
LNLionel Naccache
Lionel Naccache
JSJacobo Diego Sitt
Jacobo Diego Sitt
SEStéphane Epelbaum
Stéphane Epelbaum